![microinjector-patents](https://clearsidebio.wpengine.com/wp-content/uploads/2021/10/microinjector-patents.png)
DEVICE PATENTS
![drug-patents](https://clearsidebio.wpengine.com/wp-content/uploads/2021/10/drug-patents.jpg)
DRUG PATENTS
![disease-patent](https://clearsidebio.wpengine.com/wp-content/uploads/2021/10/disease-patent.jpg)
DISEASE PATENTS
Intellectual Property Overview
- Comprehensive IP portfolio that includes protection of: SCS delivery technology, proprietary SCS Microinjector, treatment of various conditions with SCS administration of therapeutic products
- Multiple U.S., European and International issued patents with additional pending patent applications
- Granted patents provide exclusivity for our delivery technology and product candidates to mid-2030s with pending applications potentially extending exclusivity beyond 2040
- At least the following U.S. patents apply to the products listed below. This page is intended to serve as notice under 35 U.S.C. § 287(a).
XIPERE® (triamcinolone acetonide injectable suspension), for suprachoroidal use
- US 8,197,435
- US 9,539,139
- US 9,937,075
- US 10,555,833
- US 10,390,901
- Other patents pending